Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 5, August, p. 751–760

doi: 10.17219/acem/63091

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Role of thiamine in Huntington’s disease pathogenesis: In vitro studies

Beata M. Gruber-Bzura1,A,B,C,D, Jolanta Krzysztoń-Russjan1,B,C,E, Irena Bubko1,B, Jarosław Syska1,B, Małgorzata Jaworska1,B,C,E, Adam Zmysłowski1,B,C, Magdalena Rosłon1,B,C, Janina Drozd1,B, Ewa Drozd1,B, Edyta Majorczyk1,B,C, Elżbieta L. Anuszewska1,E,F

1 Department of Biochemistry and Biopharmaceuticals, National Medicines Institute, Warszawa, Poland

Abstract

Background. Oxidative stress accompanies neurodegeneration and also causes abnormalities in thiaminedependent processes. These processes have been reported to be diminished in the brains of patients with several neurodegenerative diseases.
Objectives. The aim of this work was to conduct a comparative analysis of the impact of supplemented thiamine on the viability of human B lymphocytes with CAG abnormal expanded huntingtin gene (mHTT) (GM13509) and control, B lymphocytes without mHTT (GM14467) through the following studies: determination of the supplemented thiamine concentrations, which are effective for cell growth stimulation after incubation in thiamine deficit conditions; determination of cell capability to intake the exogenous thiamine; evaluation of exogenous thiamine influence on the profile of the genes related to thiamine and energy metabolism; determination of ATP synthesis and activities of thiamine-dependent enzymes, KGDHC and BCKDHC in the intact cells and upon the exogenous thiamine.
Material and Methods. The following methods were used: EZ4U test for cell growth analysis; HPLC for determination of thiamine intake and ATP synthesis, qRT-PCR for evaluation of the gene profiles and spectrophotometric method for KGDHC and BCKDHC activities determination.
Results. Maximal cell growth stimulation was observed at 2.5 mM in GM14467 up to 135% of the control culture and at 5.0 mM in GM13509 cells up to 165% of the control culture. Native levels of total ATP and KGDHC and BCKDHC activities in both cell types were comparable and did not changed upon thiamine deficit or supplementation. GM13509 cells showed more of an increase in growth stimulation upon thiamine supplementation than GM14467 cells and this effect was reflected in the increase of intracellular thiamine concentration.
Conclusion. The above results and reported changes in expression of GAPDH, IDH1 and SLC19A3 genes observed upon thiamine deficit conditions suggest that intracellular thiamine status and energy metabolism can have a role in HD pathogenesis.

Key words

thiamine, energy metabolism, Huntington’s DOI disease, ATP synthesis

References (31)

  1. Mochel F, Haller RG. Energy deficit in Huntington disease: Why it matters. J Clin Invest. 2011;121:493–499.
  2. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington’s disease: The current state of research with peripheral tissues. Exp Neurol. 2009;219:385–397.
  3. Arenas J, Campos Y, Ribacoba R, et al. Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol. 1998;432(3):397–400.
  4. Schapira AHV. Mitochondrial involvement in Parkinson’s disease, Huntington’s disease, hereditary spastic paraplegia and Friedreich’s ataxia. Biochim Biophys Acta. 1999;1410:159–170.
  5. Gil-Mohapel J, Brocardo PS, Christie BR. The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates? Curr Drug Targets. 2014;15(4):454–468.
  6. Gibson GE, Zhang H. Interactions of oxidative stress with thiamine homeostasis promote neurodegeneration. Neurochem Int. 2002;40:493–504.
  7. Aikawa H, Watanabe IS, Furuse T, et al. Low energy levels in thiamine-deficient encephalopathy. J Neuropathol Exp Neurol. 1984;43(3):276–287.
  8. Pekovich SR, Martin PR, Singleton CK. Thiamine deficiency decreases steady-state transketolase and pyruvate dehydrogenase but not α-ketoglutarate dehydrogenase mRNA levels in three human cell types. J Nutr. 1998;128:683–687.
  9. Jhala SS, Hazell AS. Modeling neurodegenerative disease pathophysiology in thiamine deficiency: Consequences of impaired oxidative metabolism. Neurochem Int. 2011;58(3):248–260.
  10. Akilesh S, Shaffer DJ, Roopenian D. Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis. Genome Res. 2003;13(7):719–727.
  11. Manfredi G, Yang L, Gajewski CD, Mattiazzi M. Measurements of ATP in mammalian cells. Methods. 2002;26:317–326.
  12. Katsuki H, Yoshida T, Tanegashima C, Tanaka S. Improved direct method for determination of keto acids by 2,4-dinitrophenylhydrazine. Anal Biochem. 1971;43:349–356.
  13. Marriage BJ, Clandinin MT, Macdonald IM, Glerum DM. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab. 2004;81:263–272.
  14. Pekovich SR, Poggi V, Martin PR, Singleton CK. Sensitivity to thiamine deficiency in cultures human cells in dependent on cell type and is enhanced in cells from thiamine-responsive megaloblastic anemia patients. Nutr Biochem. 1998;9:215–222.
  15. Zangen A, Shainberg A. Thiamine deficiency in cardiac cells in culture. Biochem Pharmacol. 1997;54:575–582.
  16. Bettendorff L, Mastrogiacomo F, Wins P, Kish SJ, Grisar T, Ball MJ. Low thiamine diphosphate levels in brains of patients with frontal lobe degeneration of the non-Alzheimer’s type. J Neurochem. 1997;69(5):2005–2010.
  17. Bettendorff L, Mastrogiacomo F, LaMarche J, Dozić S, Kish SJ. Brain levels of thiamine and its phosphate esters in Friedreich’s ataxia and spinocerebellar ataxia type 1. Mov Disord. 1996;11(4):437–439.
  18. Mazzola JL, Sirover MA. Reduction of glyceraldehydes-3-phosphate dehydrogenase activity in Alzheimer’s disease and in Huntington’s disease fibroblasts. J Neurochem. 2001;76(2):442–449.
  19. Senatorov VV, Charles V, Reddy PH, Tagle DA, Chuang DM. Overexpression and nuclear accumulation of glyceraldehydes-3-phosphate dehydrogenase in a transgenic mouse model of Huntington’s disease. Mol Cell Neurosci. 2003;22(3):285–297.
  20. Ganapathy V, Smith SB, Prasad PD. SLC19: The folate/thiamine transporter family. Pflugers Arch. 2004;447(5):641–646.
  21. Perluigi M, Poon HF, Maragos W, et al. Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice. Mol Cell Proteomics. 2005;4:1849–1861.
  22. Strand AD, Aragaki AK, Shaw D, et al. Gene expression in Huntington’s disease skeletal muscle: A potential biomarker. Hum Mol Genet. 2005;14(13):1863–1876.
  23. Milakovic T, Johnson GVW. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem. 2005;280(35):30773–30782.
  24. Ham D, Karska-Wysocki B. Energy and glucose pathways in thiamine deficient primary rat brain microvascular endothelial cells. Gen Physiol Biophys. 2005;24:467–474.
  25. Héroux M, Raghavendra Rao VL, Lavoie J, Richardson JS, Butterworth RF. Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer’s disease. Metab Brain Dis. 1996;11(1):81–88.
  26. Jankowska-Kulawy A, Bielarczyk H, Pawełczyk T, Wróblewska M, Szutowicz A. Acetyl-CoA deficit in brain mitochondria in experimental thiamine deficiency encephalopathy. Neurochem Int. 2010;57:851–856.
  27. Mastrogiacomo F, Bergeron C, Kish SJ. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. J Neurochem. 1993;61(6):2007–2014.
  28. Blass JP, Sheu KF, Cooper AJ, Jung EH, Gibson GE. Thiamin and Alzheimer’s disease. J Nutr Sci Vitaminol. 1992;Spec no;401–404.
  29. Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol. 1988;45(8):836–840.
  30. Shi Q, Karuppagounder SS, Xu H, Pechman D, Chen H, Gibson GE. Responses of the mitochondrial alpha-ketoglutarate dehydrogenase complex to thiamine deficiency may contribute to regional selective vulnerability. Neurochem Int. 2007;50:921–931.
  31. Krzysztoń-Russjan J, Zielonka D, Jackiewicz J, et al. A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington’s disease: Looking for biomarkers. J Bioenerg Biomembr. 2013;45(1–2):71–85.